Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR modulators for those with CF mutations or IgG supplementation.
Clinical Brief: Etiologic Evaluation and First-Line Treatment of Bronchiectasis
Main Discussion Topics
Key Points for Physicians
Notable Insights
In approximately 40% to 50% of cases, etiologic evaluation can identify host susceptibility factors that allow for targeted interventions beyond general management.
Clinical Significance
Combining universal bronchiectasis management approaches with etiology-specific interventions creates a more effective personalized treatment strategy.
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
Global Analysis Sheds Light on Women’s Cancer Trends
May 11th 2025As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.
Read More